Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Achilles Therapeutics Plc (NQ: ACHL )

0.7716 -0.0084 (-1.08%)
Streaming Delayed Price Updated: 3:57 PM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 112,211
Open 0.7800
Bid (Size) 0.7505 (13)
Ask (Size) 0.7700 (27)
Prev. Close 0.7800
Today's Range 0.7411 - 0.7900
52wk Range 0.7400 - 1.760
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
From Achilles Therapeutics PLC
Via GlobeNewswire
ACHL Stock Earnings: Achilles Therapeutics Beats EPS for Q1 2024
ACHL stock results show that Achilles Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-11.51%
-11.51%
1 Month
-8.09%
-8.09%
3 Month
-13.28%
-13.28%
6 Month
-19.32%
-19.32%
1 Year
-22.06%
-22.06%

More News

Read More
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Achilles Therapeutics: Q1 Earnings Insights
Via Benzinga
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
ACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
Exposures Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via FinancialNewsMedia
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics to Present at Upcoming Conferences
From Achilles Therapeutics PLC
Via GlobeNewswire
3 Stocks With 1,000% Upside Potential
Via InvestorPlace
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
From Achilles Therapeutics PLC
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.